Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PARANOID! TIRED OF TALKING TO YOURSELF? LET'S TALK(TTP) -- Ignore unavailable to you. Want to Upgrade?

To: Arthur Radley who wrote (44)	3/26/1998 2:04:00 PM
From: JFitnich	Respond to of 626

Thanks for clarifying the royalty position. As I stated before I was unaware of the current percentage and was going from what Sturza's report has stated. I guess I should have just spoke with the co. in the first place. I really like this co.'s outlook and the fact that NVTSY is ponying up the bucks for the Phase 3 makes it look even better. As for XOMA, it's a violation of my discipline, and it is said that discipline is more important than conviction, but I say what the hell. (not so) disciplined JF

To: Arthur Radley who wrote (44)	4/14/1998 8:43:00 AM
From: Arthur Radley	Read Replies (1) \| Respond to of 626

Interesting article in WSJ today. Lilly's Zyprexa drug appears to be headed to bring in over 1 Billion in world-wide sales. This will make it the #1 antipsychotic drug. Titan's partner, Novartis, their drug Clozaril will have sales this year of about $450 million or less. Sales will continue to drop for them as they will face generic competition. It also appears that Clozaril has serious potential side-effects with a potential blood disease and seizures. Patients have to get regular blood test. The article further states,"because of the dangers, the great research focus in the treatment of schizophrenia has been to find a drug that is as effective as Clozaril without the dangers." It is probably for these reasons that Novartis is working with Titan to bring their drug to the market.The expanding of the Phase III trials by Novartis and the spending of extra money by them, indicates (IMO) that they apparently have great faith in the potential for Iloperodine.